Library / Metabolic / Pemvidutide
GLP-1 / glucagon dual · ALT-801
Pemvidutide
Trial
ClassBalanced dual agonist
Typical routes in papersWeekly SC in trials
Half-life contextWeekly-class
EvidencePhase 2 obesity / liver-fat trials
What it is
Pemvidutide is another GLP-1/glucagon weekly shot aimed at weight and liver fat (MASH / NAFLD research).
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- People watch it for body-weight plus liver-fat reduction in trial charts.
- Glucagon activity is the “use energy, not only eat less” lever.
- Trial drug only.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Designed dual agonism intended to balance satiety (GLP-1) and energy expenditure (glucagon).
Possible side effects / caveats
Nausea, pulse changes, liver-lab monitoring in programs.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial citations | 1.2–2.4 mg weekly class in some reports | Weekly | Check current protocol papers |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.